PCI Biotech to present at DNB Nordic Healthcare Conference 2021
14 Diciembre 2021 - 4:45AM
PCI Biotech to present at DNB Nordic Healthcare Conference 2021
Oslo (Norway), 14 December 2021 – PCI Biotech
(OSE: PCIB), a clinical-stage biopharma company developing
innovative therapeutics that address significant unmet medical
needs in cancer today announced that it has been invited to present
at the DNB Nordic Healthcare Conference 2021, an Oslo based online
event hosted by DNB.
On Thursday, 16 December 2021 at 11:10 (CET),
Dr. Per Walday, CEO, will present an overview of PCI Biotech’s
proprietary platform technology via a general company presentation.
The Company is also available for 1:1 meetings with potential
partners and investors.
The presentation slides will be made available
on PCI Biotech’s website (www.pcibiotech.com) under “Other
presentations”.
Contact
information: Per
Walday,
CEO pw@pcibiotech.noMobile:
+47 917 93 429
About PCI
Biotech PCI
Biotech is a biopharmaceutical late-stage clinical development
company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative
photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:
fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction
technology for therapeutic vaccination), and
fimaNAc (nucleic acid
therapeutics delivery).
Photochemical internalisation induces triggered
endosomal release that is used to unlock the true potential of a
wide array of therapeutic modalities. The company’s lead programme
fimaChem consists of
a pivotal study in perihilar and distal bile duct cancer, an
orphan indication with a high unmet need and without approved
products. fimaVacc applies a
unique mode of action to enhance the essential cytotoxic effect of
therapeutic cancer vaccines, which works in synergy with several
other state-of-the-art vaccination technologies.
fimaNAc utilises the endosomal
release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit:
www.pcibiotech.com
Forward-looking statements
This announcement
may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of
which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024